CD44 and hepatocellular carcinoma: Impairing this axis relieved the exhausting phenotype of T cells, which motivated us to investigate the combination of anti-Spp1 mAb or anti-Cd44 mAb to remodel the TIME with anti-Pd-1 mAb for enhanced treatment efficacy of HCC.